Analysts Set uniQure (NASDAQ:QURE) PT at $23.00

Shares of uniQure (NASDAQ:QURE) have been assigned an average recommendation of “Moderate Buy” from the seven ratings firms that are covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $23.00.

QURE has been the subject of a number of research analyst reports. The Goldman Sachs Group lowered shares of uniQure from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $63.00 to $8.00 in a research report on Thursday, February 29th. Mizuho cut their price target on shares of uniQure from $7.00 to $6.00 and set a “neutral” rating on the stock in a report on Wednesday, May 8th. StockNews.com raised uniQure to a “sell” rating in a report on Friday, March 1st. Finally, HC Wainwright restated a “buy” rating and issued a $25.00 price objective on shares of uniQure in a research note on Wednesday, May 8th.

uniQure Trading Down 1.8 %

uniQure stock opened at $4.46 on Friday. The firm’s 50 day moving average price is $4.84 and its two-hundred day moving average price is $5.51. The firm has a market cap of $216.53 million, a price-to-earnings ratio of -0.72 and a beta of 1.08. The company has a debt-to-equity ratio of 0.70, a quick ratio of 9.27 and a current ratio of 9.39. uniQure has a 1 year low of $4.25 and a 1 year high of $11.95.

uniQure (NASDAQ:QURE) last released its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.31) by ($0.05). uniQure had a negative net margin of 1,562.22% and a negative return on equity of 121.60%. The firm had revenue of $8.49 million for the quarter, compared to analyst estimates of $2.58 million. On average, research analysts predict that uniQure will post -4.5 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Ikarian Capital LLC raised its stake in shares of uniQure by 198.1% in the first quarter. Ikarian Capital LLC now owns 469,133 shares of the biotechnology company’s stock valued at $2,439,000 after purchasing an additional 311,768 shares in the last quarter. Carlson Capital L P grew its position in uniQure by 16.6% in the first quarter. Carlson Capital L P now owns 227,400 shares of the biotechnology company’s stock valued at $1,182,000 after acquiring an additional 32,400 shares during the period. Covestor Ltd boosted its stake in shares of uniQure by 103.2% in the 1st quarter. Covestor Ltd now owns 53,690 shares of the biotechnology company’s stock valued at $279,000 after purchasing an additional 27,267 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in uniQure by 133.1% during the 1st quarter. Acadian Asset Management LLC now owns 613,490 shares of the biotechnology company’s stock valued at $3,189,000 after purchasing an additional 350,291 shares during the last quarter. Finally, Vanguard Group Inc. grew its stake in uniQure by 11.4% during the first quarter. Vanguard Group Inc. now owns 1,072,536 shares of the biotechnology company’s stock worth $5,577,000 after buying an additional 109,740 shares during the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.